Since AD evolves concurrently with the accumulation of Aβ, causing the expansion of tau pathology (87), these prospective DMT are essentially addressing the two pathogenic hallmarks of AD: Aβ and tau-protein (86). The gene discussed is MAPT; the disease is Alzheimer disease.